Gene Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT04910685	Phase II	Elenestinib	(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis	Recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUT \| AUS	3
NCT01738139	Phase I	Imatinib + Ipilimumab	Ipilimumab and Imatinib Mesylate in Advanced Cancer	Completed	USA	0
NCT05609942	Phase Ib/II	Elenestinib Azacitidine + Elenestinib	Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE)	Recruiting	USA \| NLD \| FRA \| ESP \| DEU \| BEL	1
NCT02638766	Phase II	Regorafenib	Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)	Completed	ITA \| FRA \| ESP	0
NCT05366816	Phase II	Regorafenib Sunitinib	ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST	Recruiting	USA	0
NCT06087263	Phase II	Regorafenib	Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.	Not yet recruiting	USA	0
NCT05734105	Phase III	Ripretinib Sunitinib	A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	Recruiting	USA \| NLD \| ITA \| GBR \| ESP \| CAN \| AUS	5
NCT01831726	Phase II	Dovitinib	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Completed	USA	0
NCT02400385	Phase II	Nivolumab + Sunitinib	A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma	Withdrawn	USA	0
NCT02029001	Phase II	Durvalumab + Tremelimumab Olaparib Pazopanib Nilotinib	Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus)	Recruiting	FRA	0
NCT04631744	Phase II	Cabozantinib	Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)	Recruiting	USA	0
NCT02401815	Phase Ib/II	PLX9486 + Sunitinib Pexidartinib + PLX9486 PLX9486	PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors	Completed	USA	0
NCT05554341	Phase II	Nilotinib + Paclitaxel	Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial	Suspended	USA	0
NCT02260505	Phase III	Imatinib	Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)	Completed	FRA	0
NCT01222143	Phase Ib/II	Cytarabine + Etoposide + Mitoxantrone Nilotinib	Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia	Terminated	CAN	0
NCT05009927	Phase II	Imatinib	Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)	Recruiting	FRA	0
NCT00812240	Phase III	Masitinib Imatinib	A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment	Terminated	USA \| FRA	1
NCT02642016	Phase I	CDX-0158	A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors	Completed	USA	0
NCT06208748	Phase II	PLX9486 + Sunitinib	SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST	Not yet recruiting	USA	0
NCT05957367	Phase Ib/II	DCC-3116 + Ripretinib Cetuximab + DCC-3116 + Encorafenib	A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies	Recruiting	USA	0
NCT01028222	Phase II	Nilotinib	A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation	Completed	USA \| NLD \| ITA \| ESP \| DEU \| CAN \| BEL \| AUS	6
NCT04936178	Phase I	NB003	A Study of NB003 in Patients With Advanced Malignancies	Recruiting	USA \| GBR \| FRA \| ESP	2
NCT02747537	Phase II	Irinotecan + Sorafenib	Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan	Withdrawn		0
NCT02693535	Phase II	Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	Recruiting	USA	0
NCT02561988	Phase I	Avapritinib	(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies	Completed	USA \| GBR	0
NCT02315625	Phase II	Everolimus Sunitinib	Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery	Terminated	USA	0
NCT04591431	Phase II	Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib	The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME)	Active, not recruiting	ITA	0
NCT04773782	Phase Ib/II	Avapritinib	A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling	Recruiting	USA \| ITA \| GBR \| FRA \| DEU \| CAN \| AUT \| AUS	1
NCT01306045	Phase II	Erlotinib Lapatinib MK2206 Sunitinib Selumetinib	Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies	Active, not recruiting	USA	0
NCT03674411	Phase II	Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus	Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy	Active, not recruiting	USA	0
NCT03109301	Phase II	Selumetinib	A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)	Withdrawn		0
NCT05160168	Phase Ib/II	THE-630	A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	Terminated	USA	0
NCT03934372	Phase Ib/II	Ponatinib	Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors	Recruiting	NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL	2
NCT02015065	Phase II	Vandetanib	Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors	Completed	USA	0
NCT03531736	Phase I	Rituximab Cyclophosphamide + Fludarabine	T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia	Active, not recruiting	USA	0
NCT05493215	Phase II	Imatinib	Imatinib TDM in GIST	Recruiting	USA	0
NCT03613532	Phase I	Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine	Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	Recruiting	USA	0
NCT01338987	Phase II	Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine	Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation	Completed	USA	0
NCT04059224	Phase II	Dabrafenib + Trametinib	TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (TraMel-WT)	Completed	BEL	0
NCT04908176	Phase I	Avapritinib + Midazolam	A Drug-drug Interaction Study of Avapritinib and Midazolam	Completed	USA	0
NCT02812693	Phase Ib/II	Imatinib + Pembrolizumab	Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification	Withdrawn		0
NCT03365661	Phase II	Nogapendekin alfa inbakicept	QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML	Withdrawn	USA	0
NCT01396408	Phase II	Temsirolimus Sunitinib	A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours	Active, not recruiting	CAN	0
NCT04598009	Phase II	Binimetinib + Imatinib	Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma	Recruiting	USA	0
NCT03297606	Phase II	Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR)	Recruiting	CAN	0
NCT04116541	Phase II	Alectinib Cabozantinib Ribociclib + Siremadlin	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)	Recruiting	FRA	0
NCT02925234	Phase II	Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab	The Drug Rediscovery Protocol (DRUP Trial) (DRUP)	Recruiting	NLD	0
NCT03158103	Phase I	Binimetinib + Pexidartinib	A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)	Completed	USA	0
NCT03165721	Phase II	Guadecitabine	A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer	Terminated	USA	0
NCT02118311	Phase II	Fludarabine Cyclophosphamide	T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After a Non-Myeloablative Umbilical Cord Blood Transplantation	Withdrawn	USA	0
NCT01396148	Phase II	Sunitinib	A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor	Completed	USA \| FRA	1
NCT04771520	Phase II	Avapritinib	Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors	Recruiting	USA	0
NCT01874665	Phase II	Ponatinib	A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor	Completed	USA	0
NCT02272998	Phase II	Ponatinib	Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.	Active, not recruiting	USA	0
NCT04487106	Phase II	Azacitidine + Trametinib + Venetoclax	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	Completed	USA	0
NCT05489237	Phase I	IDRX-42	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	Recruiting	USA \| ESP \| DEU \| BEL	0

Gene Detail

Contact

Filtering

Sorting